Top 3 Health Care Stocks That May Collapse This Quarter
Benzinga (Mon, 15-Jun 8:51 AM ET)
TG Therapeutics Shareholders Reject Executive Compensation at Meeting
TipRanks (Fri, 12-Jun 6:51 PM ET)
Market Chameleon (Wed, 10-Jun 7:08 AM ET)
Globe Newswire (Tue, 9-Jun 7:30 AM ET)
Globe Newswire (Wed, 3-Jun 7:30 AM ET)
TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference
Globe Newswire (Tue, 2-Jun 7:30 AM ET)
Globe Newswire (Mon, 1-Jun 7:30 AM ET)
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
Globe Newswire (Thu, 28-May 7:30 AM ET)
TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial
Globe Newswire (Wed, 27-May 7:30 AM ET)
Globe Newswire (Tue, 26-May 7:30 AM ET)
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
TG Therapeutics trades on the NASDAQ stock market under the symbol TGTX.
As of June 17, 2026, TGTX stock price climbed to $51.90 with 543,670 million shares trading.
TGTX has a beta of 0.42, meaning it tends to be less sensitive to market movements. TGTX has a correlation of 0.01 to the broad based SPY ETF.
TGTX has a market cap of $7.95 billion. This is considered a Mid Cap stock.
Last quarter TG Therapeutics reported $205 million in Revenue and $.18 earnings per share. This beat revenue expectation by $4 million and missed earnings estimates by -$.09.
In the last 3 years, TGTX traded as high as $52.01 and as low as $6.46.
The top ETF exchange traded funds that TGTX belongs to (by Net Assets): IJR, VTI, IWM, XBI, VB.
TGTX has outperformed the market in the last year with a price return of +45.7% while the SPY ETF gained +25.7%. TGTX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +80.4% and +41.6%, respectively, while the SPY returned +12.4% and -1.2%, respectively.
TGTX support price is $48.95 and resistance is $52.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TGTX shares will trade within this expected range on the day.